---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-23-022447"
form_type: "8-K"
ticker: "PRME"
cik: "0001894562"
company_name: "Prime Medicine, Inc."
filed_at: "2023-06-16T23:59:59+00:00"
generated_at: "2026-06-13T23:20:43.515521+00:00"
event_type: "other"
sentiment: "neutral"
materiality_score: 0.0
calibrated_materiality_score: 0.0
confidence: "high"
source: SEC EDGAR
---

# Prime Medicine elects Kelly and Schenkein to board, ratifies PwC as auditor

## Summary
- Michael Kelly elected Class I director with 64.5M for, 1.3M withheld; David Schenkein with 62.0M for, 3.7M withheld.
- Broker non-votes on director election totaled 1,517,331.
- PricewaterhouseCoopers LLP ratified as independent auditor for FY2023 with 67.3M for, 6.3K against, 11.5K abstentions.
- Annual meeting held June 14, 2023; all proposals approved by stockholders.

## SEC filing metadata
- accession: 0001628280-23-022447
- form_type: 8-K
- ticker: PRME
- cik: 0001894562
- company_name: Prime Medicine, Inc.
- filed_at: 2023-06-16T23:59:59+00:00
- event_type: other
- sentiment: neutral
- materiality_score: 0.0
- calibrated_materiality_score: 0.0
- confidence: high
- sec_items: 5.07
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1894562/000162828023022447/0001628280-23-022447-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1894562/000162828023022447/prme-20230614.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-23-022447
- JSON: https://secwatch.observer/filing/0001628280-23-022447.json
- Plain text: https://secwatch.observer/filing/0001628280-23-022447.txt

## Key facts
- Shareholder Votes
  Prime Medicine, Inc. shareholders approved Ratification of appointment of PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm for fiscal year ending December 31, 2023 at the 2023-06-14 meeting.
  - Proposal: auditor ratification
  - Outcome: passed
  - Meeting: 2023-06-14
  source text: The appointment of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for the Company’s fiscal year ending December 31, 2023 was ratified, based on the following votes:
  evidence_url: https://www.sec.gov/Archives/edgar/data/1894562/000162828023022447/0001628280-23-022447-index.htm
- Shareholder Votes
  Prime Medicine, Inc. shareholders approved Election of Michael Kelly and David Schenkein as Class I Directors at the 2023-06-14 meeting.
  - Proposal: director election
  - Outcome: passed
  - Meeting: 2023-06-14
  source text: Each of the following nominees was elected as a Class I Director to serve until the Company’s 2026 annual meeting of stockholders, and until his respective successor shall have been duly elected and qualified, based on the following votes:
  evidence_url: https://www.sec.gov/Archives/edgar/data/1894562/000162828023022447/0001628280-23-022447-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.